Phase 3 MYR301: Bulevirtide Shows Sustained Undetectability
– 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost...
Tag : European Economic Area
Bristol Myers Squibb Gets CHMP Opinion for Breyanzi in Lymphoma
Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete response Across clinical...